Cerus and the Community Blood Center of the Carolinas Enter into Agreement for the Use of INTERCEPT Platelets and Plasma

Cerus Corporation

announced today that the Community Blood Center of the Carolinas (CBCC) has signed a three-year purchase agreement for the INTERCEPT Blood System for platelets and plasma. CBCC provides over 12,000 platelet and 22,000 plasma units annually to 27 regional hospitals. "Our goal is to provide blood components of the highest possible level of quality and safety for the hospitals and patients we serve," said Martin Grable, CBCC's president and chief executive officer. "INTERCEPT-treated platelets and plasma enable us to offer an even safer choice of blood components in the Carolinas." "We are proud to work with CBCC to bring pathogen-reduced platelets and plasma to the Carolinas. We believe everyone should have access to pathogen-reduced platelets and plasma and CBCC's goal of providing blood components with the highest quality and safety standards is consistent with Cerus' own mission," commented William 'Obi' Greenman, Cerus' president and chief executive officer.